What this Trial Is About

This research aims to compare the effects of intravenous (IV) pethidine and intrathecal pethidine on shivering in females undergoing cesarean section under spinal anesthesia. The study focuses on how these two drug administration routes influence the occurrence, start time, duration, and severity of shivering. It also evaluates their impact on hemodynamic stability, nausea, vomiting, and sedation in this patient group. The study is a single-blinded, randomized, phase 3 trial involving 86 women aged 20 to 40 years old with physical status ASA II, scheduled for elective cesarean section. Participants will be randomly assigned to one of two groups: one receiving IV pethidine 0.5 mg/kg mixed in saline before surgery, and the other receiving intrathecal pethidine 0.2 mg/kg combined with bupivacaine 0.5% during spinal anesthesia. Spinal anesthesia will be performed at the L3-L4 or L4-L5 level, and patients will not be actively warmed during surgery. Standard protocols will manage hypotension, bradycardia, and vomiting if they occur. Throughout the surgery and for two hours after, vital signs and body temperature will be regularly monitored, and shivering will be assessed every 15 minutes during surgery and every 30 minutes postoperatively using the Tsai and Chu Scale. Researchers will record the frequency, timing, length, and intensity of shivering, along with any side effects like nausea, vomiting, and sedation. The operating room and recovery area temperatures will be maintained between 21 and 24 degrees Celsius to control environmental factors.

Comparing Prophylactic Intravenous Pethidine and Intrathecal Pethidine in Preventing Post Spinal Shivering in Caesarean Section